Transforming cancer diagnostics through liquid biopsy mRNA.
Focused on molecular liquid biopsy cancer diagnostics since 2014 — a commercial extension of decades of academic and medical research into non-invasive tests for cancer and other diseases.
Transform cancer diagnostics through innovative liquid biopsy mRNA technology.
Wren Laboratories is a CLIA, CAP, NYSDOH and ISO 15189-certified clinical testing and R&D laboratory established in 2014.
Our mission is to pioneer innovative in vitro diagnostics using machine learning and liquid biopsy-RNA technologies — enhancing detection of minimal residual disease, predicting and monitoring cancer response to therapies, and improving prognosis and outcomes.
Science, innovation and collaboration.
Be it blood or saliva, our molecular cancer diagnostics provide actionable disease information in real time.
Committed to science
Scientific discipline and the benefits of rigorously applied molecular science.
A pioneering spirit
Combating cancer effectively demands an innovative approach and cutting-edge techniques.
True collaborators
Managing cancer requires inspired teamwork. We are open, connected and fully collaborative.
Excellence in execution
Across research, clinical testing and data analysis.
Focused on success
The stakes could not be higher; our principal focus is positively impacting the lives of cancer patients.
Certified to the highest standards.
Every test is performed in our accredited clinical laboratory in Branford, Connecticut.
CAP-accredited. CLIA-certified.
All molecular research, testing and analysis is conducted at our clinical laboratory in Branford, CT. Most of our liquid biopsy tests use real-time quantitative PCR (qPCR) on RNA isolated from peripheral blood or saliva — known for sensitive, specific and reproducible gene-expression measurement.
Our experienced, highly trained technicians follow extensive quality-control procedures at every stage:
RNA quantity & quality
Sufficient purified RNA for all reactions, meeting purity criteria including checks for excess genomic DNA.
Gene-specific ranges
Each gene product’s measured quantity must fall within established ranges.
Efficiency of qPCR
Amplification, doubling target each cycle, must fall within defined limits.
Accuracy & precision
Each gene tested must meet established accuracy and precision specifications.
Our scientific strategy and forward focus.
We identify gene signatures that categorize the state of a disease — primarily cancer — to identify recurrence in time or assess whether therapy is working.
Algorithms
Biomathematical algorithms identify gene-signaling clusters that reveal tumor proliferation and metastatic potential.
mRNA
First identification of circulating neuroendocrine and other tumor-cell mRNAs — signatures that detect disease missed by standard of care, and predict growth, metastasis and therapy sensitivity.
Beyond NETs
Blood biomarkers for prostate cancer (PROSTest), prediction of PRRT response (PPQ), and saliva-based PCR tests for different cancers.
Pipeline
Diagnostics in development for breast, colon, lung, melanoma, myeloma and pancreatic cancer — and non-cancer diseases such as endometriosis.
Providers, order your test here
Order NETest 2.0® or PROSTest® through our portal or with the requisition form — kits ship directly to your office.